Evidence map›Paper›PMID 42513117›Full record

ArticleMolecules (Basel, Switzerland)2026

Development of a Hypoxia-Triggered Supramolecular Nanoplatform for Synergistic Hypoxia Alleviation and Amplified Photodynamic Cancer Therapy.

Ningning Luo, Yiliang Wu, Jiaxin Zheng, Chi Zhang, Xiaoyang Qian, Caoqing Ji, Aiqing Jiang, Yong Ling, Xin Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ningning LuoJiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, School of Pharmacy, Nantong University, Nantong 226001, China.
Yiliang WuJiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, School of Pharmacy, Nantong University, Nantong 226001, China.
Jiaxin ZhengJiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, School of Pharmacy, Nantong University, Nantong 226001, China.
Chi ZhangJiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, School of Pharmacy, Nantong University, Nantong 226001, China.
Xiaoyang QianJiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, School of Pharmacy, Nantong University, Nantong 226001, China.
Caoqing JiJiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, School of Pharmacy, Nantong University, Nantong 226001, China.
Aiqing JiangJiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing 210093, China.
Yong LingJiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, School of Pharmacy, Nantong University, Nantong 226001, China.
Xin LiuJiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, School of Pharmacy, Nantong University, Nantong 226001, China.

Funding

Key Natural Science Foundation of Jiangsu Higher Education Institutions 20KJA350002National Natural Science Foundation of China 22001133, 82473840Postgraduate Research & Practice Innovation Program of Jiangsu Province KYCX25_3844the large instruments open foundation of Nantong University KFJN2270, KFJN2367
6 · The paper itself

Abstract

Photodynamic therapy (PDT) represents a highly promising modality for cancer treatment; however, its clinical success is significantly restricted by the hypoxic nature of the tumor microenvironment (TME). Hypoxia also upregulates hypoxia-inducible factor-1α (HIF-1α) expression, thereby exacerbating tumor malignancy. To tackle this challenge, we engineered a hypoxia-activatable supramolecular nanoplatform (GH@CyNPs) capable of dual hypoxia reversal and amplification of PDT efficacy. The nanoplatform was constructed via host-guest interactions between a water-soluble pillar[5]arene (

Indexed as

HypoxiaNanoparticlesNeoplasmsPhotochemotherapyPhotosensitizing AgentsAnimalsCatalaseCell Line, TumorGlucose OxidaseHumansHypoxia-Inducible Factor 1, alpha SubunitIndazolesMiceReactive Oxygen SpeciesTumor Microenvironment3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazoleCatalaseGlucose OxidaseHypoxia-Inducible Factor 1, alpha SubunitIndazolesPhotosensitizing AgentsReactive Oxygen Specieshypoxia-inducible factor 1α (HIF-1α)photodynamic therapy (PDT)supramolecular assemblytumor microenvironment

Identifiers

PMID42513117
PMCPMC13414287

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.